↓ Skip to main content

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Overview of attention for article published in Oncotarget, March 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
58 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Published in
Oncotarget, March 2015
DOI 10.18632/oncotarget.3387
Pubmed ID
Authors

Scheffler, M, Schultheis, A, Teixido, C, Michels, S, Morales-Espinosa, D, Viteri, S, Hartmann, W, Merkelbach-Bruse, S, Fischer, R, Schildhaus, H-U, Fassunke, J, Sebastian, M, Serke, M, Kaminsky, B, Randerath, W J, Gerigk, U, Ko, Y-D, Krüger, S, Schnell, R, Rothe, A, Kropf-Sanchen, C, Heukamp, L C, Rosell, R, Büttner, R, Wolf, J

Abstract

While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1- positive patients. 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations. ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Japan 1 2%
Unknown 56 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 19%
Other 8 14%
Student > Bachelor 8 14%
Student > Ph. D. Student 7 12%
Unspecified 6 10%
Other 18 31%
Readers by discipline Count As %
Medicine and Dentistry 34 59%
Unspecified 10 17%
Biochemistry, Genetics and Molecular Biology 3 5%
Agricultural and Biological Sciences 3 5%
Economics, Econometrics and Finance 2 3%
Other 6 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2016.
All research outputs
#6,400,413
of 7,396,084 outputs
Outputs from Oncotarget
#4,722
of 6,668 outputs
Outputs of similar age
#180,401
of 213,635 outputs
Outputs of similar age from Oncotarget
#160
of 222 outputs
Altmetric has tracked 7,396,084 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,668 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,635 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 222 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.